Teva Identifies Teriparatide Importance Amid US Launch Drought

Israeli Firm Sees 15% North America Gx Sales Decline In Q1

04 May 2022

Teva acknowledged that it was “not independent of the macro environment in the US,” as it saw another significant drop off for its North America generics business amid a lack of new launches. The Israeli giant took the unusual step of singling out a complex generic asset – its proposed generic to Eli Lilly’s Forteo – as “the most important” potential launch for its 2022 top line.

Balloons — Teva singled out teriparatide among its 2022 opportunities • Source: Shutterstock

Teva has described its proposed generic version of Eli Lilly’s Forteo (teriparatide) as “the most important” potential US generic launch this year, “one which would be a significant contributor to our sales in 2022,” despite development partner Antares Pharma electing not to include any US teriparatide revenues in its 2022 annual financial guidance.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

What’s Next? Five Things To Look Out For In May

01 May 2025

• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

30 Apr 2025

• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

30 Apr 2025

• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.